ReviewFrontiers in immunology2026
Beyond the usual suspects: rethinking post-stroke immunosuppression.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic stroke extends far beyond the hyperacute vascular event. In addition to the immediate ischemic injury, patients frequently develop systemic complications that significantly influence outcome. Among these, a biphasic immune response has emerged as a central feature: an early inflammatory reaction followed by a state of peripheral immunosuppression. This immunosuppressive phase has been consistently associated with increased susceptibility to post-stroke infections, particularly pneumonia, thereby contributing to morbidity and mortality. Multiple mechanisms have been implicated in the development of stroke-induced immunosuppression, including activation of the autonomic nervous system and the hypothalamic-pituitary-adrenal axis, the release of damage-associated molecular patterns (DAMPs), reprogramming of bone marrow hematopoiesis, and peripheral neutrophil activation with downstream effects on lymphocyte survival. While these pathways are often studied in isolation, accumulating evidence suggests that they may interact within a coordinated neuroimmune network. In this review, we not only summarize the current understanding of the mechanisms underlying post-stroke immunosuppression but also explore how these processes may converge and influence one another. Finally, we discuss the unresolved question of whether this immunosuppressive state represents an adaptive response aimed at protecting the injured brain or a maladaptive bystander consequence of disrupted neuroimmune homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.